Henan Newland Pharmaceutical Co. Ltd. A Net Assets
Henan Newland Pharmaceutical Co. Ltd. A net assets. Based on the latest financial reports, Henan Newland Pharmaceutical Co. Ltd. A (301277) has net assets worth CN¥1.59 Billion CNY (≈ $232.15 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.82 Billion ≈ $266.71 Million USD) and total liabilities (CN¥236.14 Million ≈ $34.55 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Henan Newland Pharmaceutical Co. Ltd. A to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.59 Billion |
| % of Total Assets | 87.04% |
| Annual Growth Rate | 37.7% |
| 5-Year Change | 281.67% |
| 10-Year Change | N/A |
| Growth Volatility | 90.01 |
Net Assets of Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
Net assets of Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2025. This chart illustrates how Henan Newland Pharmaceutical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Henan Newland Pharmaceutical Co. Ltd. A to measure how much of total assets are equity-financed.
Annual Net Assets for Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
The table below shows the annual net assets of Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2025. For live market cap and overall valuation, see how much is Henan Newland Pharmaceutical Co. Ltd. A worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.55 Billion ≈ $226.96 Million |
+0.52% |
| 2024-12-31 | CN¥1.54 Billion ≈ $225.80 Million |
+6.45% |
| 2023-12-31 | CN¥1.45 Billion ≈ $212.11 Million |
+6.64% |
| 2022-12-31 | CN¥1.36 Billion ≈ $198.89 Million |
+234.47% |
| 2021-12-31 | CN¥406.38 Million ≈ $59.47 Million |
+29.67% |
| 2020-12-31 | CN¥313.39 Million ≈ $45.86 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Henan Newland Pharmaceutical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 222.5% over the analyzed period, indicating profitable operations and earnings retention.
Henan Newland Pharmaceutical Co. Ltd. A Net Assets Breakdown (December 2025)
Henan Newland Pharmaceutical Co. Ltd. A net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥507.92 Million | 32.74% |
| Other Components | CN¥1.04 Billion | 67.26% |
| Total Equity | CN¥1.55 Billion | 100.00% |
Henan Newland Pharmaceutical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Henan Newland Pharmaceutical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WashTec AG
XETRA:WSU
|
$507.21 Million |
|
Sam-A Aluminiu
KO:006110
|
$507.32 Million |
|
Arvind Fashions Limited
NSE:ARVINDFASN
|
$507.47 Million |
|
Fineos Corporation Holdings Plc
AU:FCL
|
$507.50 Million |
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
$507.06 Million |
|
Suzhou Xingye Material Tech
SHG:603928
|
$507.03 Million |
|
Xinjiang Ba Yi Iron & Steel Co Ltd
SHG:600581
|
$506.94 Million |
|
Iperionx Ltd
AU:IPX
|
$506.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Henan Newland Pharmaceutical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,542,189,227 to 1,551,337,347, a change of 9,148,120 (0.6%).
- Net income of 121,247,725 contributed positively to equity growth.
- Dividend payments of 112,022,400 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥121.25 Million | +7.82% |
| Dividends Paid | CN¥112.02 Million | -7.22% |
| Other Changes | CN¥-77.21K | -0.0% |
| Total Change | CN¥- | 0.59% |
Book Value vs Market Value Analysis
This analysis compares Henan Newland Pharmaceutical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.92x to 2.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥1.49 | CN¥8.84 | x |
| 2021-12-31 | CN¥1.37 | CN¥8.84 | x |
| 2022-12-31 | CN¥3.46 | CN¥8.84 | x |
| 2023-12-31 | CN¥3.69 | CN¥8.84 | x |
| 2024-12-31 | CN¥3.93 | CN¥8.84 | x |
| 2025-12-31 | CN¥3.96 | CN¥8.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Henan Newland Pharmaceutical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.82%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.03%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.15x
- Recent ROE (7.82%) is below the historical average (17.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 37.80% | 27.35% | 0.83x | 1.67x | CN¥87.12 Million |
| 2021 | 28.56% | 22.38% | 0.77x | 1.66x | CN¥74.73 Million |
| 2022 | 9.76% | 21.09% | 0.41x | 1.13x | CN¥-3.29 Million |
| 2023 | 10.98% | 24.40% | 0.40x | 1.11x | CN¥14.18 Million |
| 2024 | 11.26% | 23.90% | 0.40x | 1.18x | CN¥19.41 Million |
| 2025 | 7.82% | 18.03% | 0.38x | 1.15x | CN¥-33.89 Million |
Industry Comparison
This section compares Henan Newland Pharmaceutical Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,405,673
- Average return on equity (ROE) among peers: 7.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Henan Newland Pharmaceutical Co. Ltd. A (301277) | CN¥1.59 Billion | 37.80% | 0.15x | $507.18 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $360.39 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.73 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.04 Billion | 4.29% | 0.46x | $2.58 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.20 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $18.14 Billion | 17.33% | 0.53x | $14.52 Billion |
| Hainan Haiyao Co Ltd (000566) | $491.82 Million | 6.71% | 1.19x | $755.58 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $272.98 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $920.83 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $7.25 Billion | 17.08% | 0.09x | $3.02 Billion |
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naph… Read more